Neumora Reveals Mid-Stage Data For Fully Funded, Phase III-Ready Depression Drug

Private Biotech Has Raised $650m To Date

 
• By Mandy Jackson
  
Fear, loneliness, depression, abuse, addiction
Neumora's navacaprant aims to treat anhedonia, an inability to experience pleasure or joy, in depression patients • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D